Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection.
Clin Infect Dis
; 66(2): 289-292, 2018 01 06.
Article
em En
| MEDLINE
| ID: mdl-29020359
ABSTRACT
We assessed the effectiveness and safety of sofosbuvir (SOF) combined with ledipasvir (LDV) or daclatasvir (DCV) in 12 heart transplant recipients with chronic hepatitis C virus (HCV). The sustained virologic response (SVR12) rate was 100% [95% confidence interval [CI] 75.8%-100%]. All patients tolerated treatment well without interruption, death, or serious adverse events.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Benzimidazóis
/
Transplante de Coração
/
Hepatite C Crônica
/
Transplantados
/
Fluorenos
/
Sofosbuvir
/
Imidazóis
Tipo de estudo:
Observational_studies
/
Risk_factors_studies
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Clin Infect Dis
Assunto da revista:
DOENCAS TRANSMISSIVEIS
Ano de publicação:
2018
Tipo de documento:
Article